Based on the above considerations, we conclude that StAR could serve as a novel diagnostic marker selective for ER+/PR+ BC subtypes and that pharmacological targeting of this protein, either blockage of its function or suppression of its expression, has the potential for treatment of hormone-sensitive BC. Here, PGR is linked to breast cancer.